rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-603-608rsp-3230Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL OBSERVATIONКлинический случай применения олокизумаба у пациента с диффузной формой системной склеродермииClinical case of olokizumab treatment in a patient with diffuse systemic sclerosishttps://orcid.org/0000-0001-8598-0391КувардинЕ. С.KuvardinE. S.

197341, Санкт-Петербург, ул. Аккуратова, 2

197341, Saint Petersburg, Akkuratova str., 2

https://orcid.org/0000-0001-6697-4308АндреевД. Ю.AndreevD. Yu.

197110, Санкт-Петербург, Левашовский просп., 24

197110, Saint Petersburg, Levashovsky avenue, 24

https://orcid.org/0000-0001-7174-8719ЯстребовП. А.YastrebovP. A.

197110, Санкт-Петербург, Левашовский просп., 24

197110, Saint Petersburg, Levashovsky avenue, 24

https://orcid.org/0000-0002-7590-742XМячиковаВ. Ю.MyachikovaV. Yu.

197341, Санкт-Петербург, ул. Аккуратова, 2

197341, Saint Petersburg, Akkuratova str., 2

https://orcid.org/0000-0002-8591-7488БухановаД. В.BukhanovaD. V.

119421, Москва, Ленинский просп., 111, корп. 1

119421,Moscow, Leninsky avenue, 111, korpus 1 

https://orcid.org/0000-0001-9528-9377КарповаД. В.KarpovaD. V.

197341, Санкт-Петербург, ул. Аккуратова, 2

197341, Saint Petersburg, Akkuratova str., 2

https://orcid.org/0000-0003-4896-1516МаликовК. Н.MalikovK. N.

197341, Санкт-Петербург, ул. Аккуратова, 2

197341, Saint Petersburg, Akkuratova str., 2

https://orcid.org/0000-0003-2685-1623СамсоновМ. Ю.SamsonovM. Yu.

119421, Москва, Ленинский просп., 111, корп. 1

119421,Moscow, Leninsky avenue, 111, korpus 1 

https://orcid.org/0000-0003-2427-4148МаслянскийА. Л.MaslyanskiyA. L.

197341, Санкт-Петербург, ул. Аккуратова, 2199034, Санкт-Петербург, Университетская наб., 7–9

197341, Saint Petersburg, Akkuratova str., 2199034, Saint Petersburg, Universitetskaya embankment, 7–9

ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава РоссииРоссияAlmazov National Medical Research CentreRussian FederationКлиника эстетической медицины и цифровой стоматологии MEDALLРоссияClinic of Esthetic Medicine and Digital Dentistry MEDALLRussian FederationГруппа компаний «Р-Фарм»РоссияR-Pharm GroupRussian FederationФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России; ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияAlmazov National Medical Research Centre; Saint-Petersburg State UniversityRussian Federation202211112022605603608Copyright © Кувардин Е.С., Андреев Д.Ю., Ястребов П.А., Мячикова В.Ю., Буханова Д.В., Карпова Д.В., Маликов К.Н., Самсонов М.Ю., Маслянский А.Л., 20222022Кувардин Е.С., Андреев Д.Ю., Ястребов П.А., Мячикова В.Ю., Буханова Д.В., Карпова Д.В., Маликов К.Н., Самсонов М.Ю., Маслянский А.Л.Kuvardin E.S., Andreev D.Y., Yastrebov P.A., Myachikova V.Y., Bukhanova D.V., Karpova D.V., Malikov K.N., Samsonov M.Y., Maslyanskiy A.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3230

Подходы к лечению диффузной формы системной склеродермии окончательно не разработаны. Уровни доказательности эффективности доступных в клинической практике лекарственных препаратов при этом заболевании низкие. В связи с чем необходим поиск новых схем лечения этой нозологической формы. В представленной статье описан клинический случай применения олокизумаба у пациента с диффузной формой системной склеродермии с поражением легких, полисерозитом, тяжелыми микроциркуляторными нарушениями.

Treatment algorithms for systemic sclerosis have not been completely developed. Effectivity of medications are usually used in clinical practice has a low level of evidence. Therefore, it is necessary to find a new treatment approaches for this nosological form. In the paper described clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis with interstitial lung disease, polyserositis, severe microcirculatory alterations.

системная склеродермияолокизумабинтерлейкин-6systemic sclerosisolokizumabinterleukin - 6Referencesvan den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755. doi:10.1136/annrheumdis-2013-204424van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755. doi:10.1136/annrheumdis-2013-204424Park EH, Strand V, Oh YJ, Song YW, Lee EB. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. Arthritis Res Ther. 2019;21(1):61. Published 2019 Feb 15. doi:10.1186/s13075-019-1842-xPark EH, Strand V, Oh YJ, Song YW, Lee EB. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. Arthritis Res Ther. 2019;21(1):61. Published 2019 Feb 15. doi:10.1186/s13075-019-1842-xvan Leeuwen NM, Ciaffi J, Liem SIE, et al. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology (Oxford). 2021;60(8):3646– 3655. doi:10.1093/rheumatology/keaa827van Leeuwen NM, Ciaffi J, Liem SIE, et al. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology (Oxford). 2021;60(8):3646– 3655. doi:10.1093/rheumatology/keaa827Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9Yen EY, Singh DR, Singh RR. Trends in Systemic Sclerosis Mortality Over Forty-Eight Years, 1968–2015: A US Population-Based Study. Arthritis Care Res (Hoboken). 2021;73(10):1502–1510. doi:10.1002/acr.24411Yen EY, Singh DR, Singh RR. Trends in Systemic Sclerosis Mortality Over Forty-Eight Years, 1968–2015: A US Population-Based Study. Arthritis Care Res (Hoboken). 2021;73(10):1502–1510. doi:10.1002/acr.24411Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi:10.1136/annrheumdis-2016-209909Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi:10.1136/annrheumdis-2016-209909Naidu GSRSNK, Sharma SK, Adarsh MB, et al. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a doubleblind, placebo-controlled, randomized trial. Rheumatol Int. 2020;40(2):207–216. doi:10.1007/s00296-019-04481-8Naidu GSRSNK, Sharma SK, Adarsh MB, et al. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a doubleblind, placebo-controlled, randomized trial. Rheumatol Int. 2020;40(2):207–216. doi:10.1007/s00296-019-04481-8Ананьева Л.П. Современная терапия интерстициальных пневмоний, ассоциированных с системной склеродермией. Научно-практическая ревматология. 2020;58(5):520–531.Ананьева Л.П. Современная терапия интерстициальных пневмоний, ассоциированных с системной склеродермией. Научно-практическая ревматология. 2020;58(5):520–531.Bruni T, Varone F. The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe (Sheff). 2020;16(2):200005. doi:10.1183/20734735.0005-2020Bruni T, Varone F. The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe (Sheff). 2020;16(2):200005. doi:10.1183/20734735.0005-2020de Figueiredo Caldas MMV, de Azevedo KPM, de França Nunes AC, et al. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. Adv Rheumatol. 2021;61(1):15. Published 2021 Feb 27. doi:10.1186/s42358-021-00170-yde Figueiredo Caldas MMV, de Azevedo KPM, de França Nunes AC, et al. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. Adv Rheumatol. 2021;61(1):15. Published 2021 Feb 27. doi:10.1186/s42358-021-00170-yKhanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial [published correction appears in Lancet. 2018 Apr 7;391(10128):1356]. Lancet. 2016;387(10038):2630–2640. doi:10.1016/S0140-6736(16)00232-4Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial [published correction appears in Lancet. 2018 Apr 7;391(10128):1356]. Lancet. 2016;387(10038):2630–2640. doi:10.1016/S0140-6736(16)00232-4Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Respir Med. 2020 Oct;8(10):e75] [published correction appears in Lancet Respir Med. 2021 Mar;9(3):e29]. Lancet Respir Med. 2020;8(10):963–974. doi:10.1016/S2213-2600(20)30318-0Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Respir Med. 2020 Oct;8(10):e75] [published correction appears in Lancet Respir Med. 2021 Mar;9(3):e29]. Lancet Respir Med. 2020;8(10):963–974. doi:10.1016/S2213-2600(20)30318-0Невская Т.А., Новиков А.А., Александрова Е.Н., Мач Э.С., Запрягаева М.Н., Сперанский А.И., Гусева Н.Г., Ананьева Л.П. Клиническое значение высокочувствительного С-реактивного белка при системной склеродермии. Научно-практическая ревматология. 2007;45(4):10–17.Невская Т.А., Новиков А.А., Александрова Е.Н., Мач Э.С., Запрягаева М.Н., Сперанский А.И., Гусева Н.Г., Ананьева Л.П. Клиническое значение высокочувствительного С-реактивного белка при системной склеродермии. Научно-практическая ревматология. 2007;45(4):10–17.Cardonea nu A, Burlui AM, Macovei LA, et al.. Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?. Biomedicines. 2022;10(2):318. Published 2022 Jan 29. doi:10.3390/biomedicines10020318Cardonea nu A, Burlui AM, Macovei LA, et al.. Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?. Biomedicines. 2022;10(2):318. Published 2022 Jan 29. doi:10.3390/biomedicines10020318Ананьева ЛП. Перспективы применения тоцилизумаба при системной склеродермии. Научно-практическая ревматология. 2015;53(6):632–640.Ananyeva LP Prospects for using tocilizumab in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):632–40 (In Russ.). doi: 10.14412/1995-4484-2015-632-640Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?. BioDrugs. 2018;32(6):531–546. doi:10.1007/s40259-018-0320-3Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?. BioDrugs. 2018;32(6):531–546. doi:10.1007/s40259-018-0320-3Hosoya H, Derk CT. Clinically Symptomatic Pericardial Effusions in Hospitalized Systemic Sclerosis Patients: Demographics and Management. Biomed Res Int. 2018;2018:6812082. Published 2018 Jun 4. doi:10.1155/2018/6812082Hosoya H, Derk CT. Clinically Symptomatic Pericardial Effusions in Hospitalized Systemic Sclerosis Patients: Demographics and Management. Biomed Res Int. 2018;2018:6812082. Published 2018 Jun 4. doi:10.1155/2018/6812082Ufuk F, Çakmak P, Sağtaş E, et al. Extra-parenchymal chest HRCT findings of patients with systemic sclerosis at the time of initial diagnosis. Bezmialem Science. 2018;7(2):101–106. doi:10.14235/bs.2018.2427Ufuk F, Çakmak P, Sağtaş E, et al. Extra-parenchymal chest HRCT findings of patients with systemic sclerosis at the time of initial diagnosis. Bezmialem Science. 2018;7(2):101–106. doi:10.14235/bs.2018.2427Ocampo V, Haaland D, Legault K, et al.. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a pa - tient with systemic lupus erythematous. BMJ Case Rep. 2016;2016: bcr2016215423. Published 2016 Aug 8. doi:10.1136/bcr-2016-215423Ocampo V, Haaland D, Legault K, et al.. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a pa - tient with systemic lupus erythematous. BMJ Case Rep. 2016;2016: bcr2016215423. Published 2016 Aug 8. doi:10.1136/bcr-2016-215423Yoshida S, Takeuchi T, Sawaki H, et al. Successful treatment with tocilizumab of pericarditis associated with rheumatoid arthritis. Mod Rheumatol. 2014;24(4):677–680. doi:10.3109/14397595.2013.874733Yoshida S, Takeuchi T, Sawaki H, et al. Successful treatment with tocilizumab of pericarditis associated with rheumatoid arthritis. Mod Rheumatol. 2014;24(4):677–680. doi:10.3109/14397595.2013.874733Zacay G, Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Pract Res Clin Rheumatol. 2018;32(4):563–571. doi:10.1016/j.berh.2019.01.011Zacay G, Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Pract Res Clin Rheumatol. 2018;32(4):563–571. doi:10.1016/ j.berh.2019.01.011Kawaguchi Y. Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis. Journal of Scleroderma and Related Disorders. 2017;2(2):6–12. doi:10.5301/jsrd.5000258Kawaguchi Y. Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis. Journal of Scleroderma and Related Disorders. 2017;2(2):6–12. doi:10.5301/jsrd.5000258Hernández-Sánchez J, Harlow L, Church C, et al. Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hyperten - sion. Pulm Circ. 2018;8(1):2045893217735820. doi:10.1177/2045893217735820Hernández-Sánchez J, Harlow L, Church C, et al. Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hyperten - sion. Pulm Circ. 2018;8(1):2045893217735820. doi:10.1177/ 2045893217735820

The authors declare that there are no conflicts of interest present.